| 生物活性 | |||
|---|---|---|---|
| 靶点 |
|
||
| 描述 | Rociletinib (CO-1686) is an orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M, and the Ki values for EGFRL858R/T790M and EGFRWT are 21.5 nM and 303.3 nM, respectively[1]. | ||
| 细胞研究 | |||||
|---|---|---|---|---|---|
| 细胞系 | 浓度 | 检测类型 | 检测时间 | 活性说明 | 数据源 |
| A431 | ~5 μM | Kinase assay | inhibits pEGFR with IC50 of >4331 nM | 24065731 | |
| A431 | ~5 μM | Growth inhibitory assay | GI50=547 nM | 24065731 | |
| Ba/F3 (ASV) | ~10 μM | Growth inhibitory assay | IC50=5290 nM | 26515464 | |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
1.80mL 0.36mL 0.18mL |
9.00mL 1.80mL 0.90mL |
18.00mL 3.60mL 1.80mL |
| 参考文献 |
|---|